SMITH & NEPHEW PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 978.8 GBX | -0.39% |
|
-4.37% | -9.24% |
Financials (USD)
| Sales 2024 * | 5.82B | Sales 2025 * | 6.12B | Capitalization | 10.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M | Net income 2025 * | 694M | EV / Sales 2024 * | 2.31 x |
| Net Debt 2024 * | 2.56B | Net Debt 2025 * | 2.23B | EV / Sales 2025 * | 2.14 x |
| P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
16.2
x | Employees | 18,452 |
| Yield 2024 * |
3.04% | Yield 2025 * |
3.41% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More recommendations
More press releases
More news
| 1 day | -0.39% | ||
| 1 week | -4.37% | ||
| Current month | -0.02% | ||
| 1 month | -0.47% | ||
| 3 months | -13.72% | ||
| 6 months | -4.46% | ||
| Current year | -9.24% |
1 week
967.80
1 033.50
1 month
965.001 033.50
Current year
946.001 181.50
1 year
887.001 269.00
3 years
887.001 601.50
5 years
887.002 023.00
10 years
881.002 023.00
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.16% | 14 M€ | -5.30% | ||
| 0.52% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 978.8 | -0.39% | 3,084,127 |
| 24-05-23 | 982.6 | -3.19% | 3,374,716 |
| 24-05-22 | 1,015 | -0.44% | 2,238,314 |
| 24-05-21 | 1,020 | -0.34% | 1,540,881 |
| 24-05-20 | 1,023 | -0.05% | 1,723,877 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am EDT
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.48
USD
Average target price
16.34
USD
Spread / Average Target
+30.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.24% | 10.88B | |
| +12.05% | 128B | |
| +0.29% | 8.76B | |
| +36.99% | 5.48B | |
| -21.98% | 4.72B | |
| +8.02% | 3.43B | |
| -10.32% | 2.76B | |
| -12.33% | 2.06B | |
| -13.53% | 1.92B | |
| -28.80% | 1.65B |
- Stock Market
- Equities
- SN. Stock
